CGS 19755: a novel competitive N-methyl-D-aspartate (NMDA) receptor antagonist with anticonvulsant, anxiolytic and anti-ischemic properties
Related Experiment Videos
D A Bennett1, J Lehmann, P S Bernard
1Research Department, CIBA-Geigy Corporation, Summit, NJ 07901.
Progress in Clinical and Biological Research
|January 1, 1990
Abstract:
CGS 19755 is a potent and selective competitive antagonist at NMDA receptors in the brain. In preclinical animal tests, the compound produces anticonvulsant, anxiolytic and anti-ischemic effects. CGS 19755 is not very active when administered orally, and intravenous administration is the most practical for clinical application. The anti-ischemic potential of CGS 19755 provides the most attractive application for clinical investigation.